CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

INTRODUCTION: The cytomegalovirus (CMV) antigen, pp65, is ubiquitously expressed in malignant glioma and medulloblastoma but not in healthy brain. The objective of this Phase I trial (NCT03299309) was to assess the safety and feasibility of a novel pp65 peptide vaccine (PEP-CMV) in children and youn...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Eric, Landi, Daniel, Lipp, Eric, Balajonda, Bea, Herndon, James, Buckley, Evan, Flahiff, Charlene, Jaggers, Denise, Schroeder, Kristin, Randazzo, Dina, Desjardins, Annick, Johnson, Maggie, Peters, Katherine, Khasraw, Mustafa, Malinzak, Michael, Mitchell, Duane, Ashley, David, Sampson, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Trials: Immunologic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650420/
http://dx.doi.org/10.1093/neuonc/noaa215.155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650420/
http://dx.doi.org/10.1093/neuonc/noaa215.155

Ejemplares similares